Webinars

Speaker:  J. Lowry Curley, PhD, Co-Founder and CEO of AxoSim

Take an in-depth look at AxoSim’s case study on chemotherapeutic drug induced peripheral neuropathy and how this research is leading to the development of AxoSim’s NerveSim® 2.0 platform.

AxoSim assessed NerveSim’s ability to screen for implications of functional and structural nerve dysfunction in chemotherapy-induced peripheral neuropathy. First, this research demonstrates that NerveSim accurately recreates axonal growth, orientation, and function analogous to mature nerve anatomy. By screening known neurotoxic compounds, AxoSim established the potential for its model to prove not only whether a drug is toxic, but to also provide insights into the mechanism of that toxicity. It’s the first 3D in vitro model to collect electrophysiological and histomorphic metrics to assess in vivo pathophysiology.

*All times are Eastern Time Zone

Speaker: Thomas Hartung, MD, PhD, Consulting VP of Scientific Affairs at AxoSim and Professor and Chair, Johns Hopkins University

Neurological impairments are usually irreversible because of limited regeneration in the central nervous system. The regenerative capacity of stem cells makes them an attractive candidate for transplantation therapies, with many stem cells showing promise in basic research and preclinical trials.

Learn about how advances in iPSC-derived organoid models recapitulate the “real” brain environment for CNS precision medicine.

Speaker: Anup Sharma, PhD, Lead Scientist at AxoSim

Learn about the use of Human Schwann Cells in preclinical peripheral neuropathy research. In this webinar, Dr. Sharma presents on our human peripheral neurotoxicity assay with Schwann Cells which recapitulates peripheral neuropathy in small molecules and antibody drug conjugates.

Speaker: Rakesh Dixit, PhD, DABT, President and CEO, Bionavigen

Peripheral Neuropathy is a common side effect of many Antibody Drug Conjugates. What are the pitfalls of using traditional preclinical testing models? Learn about the past, present, and future of ADCs and predictive assays testing peripheral neuropathy side effects.